MRK catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 31, 2026Sponsor estimate | NCT07300085A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Healthy Participants | MRKLead | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT07300085A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Healthy ParticipantsRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 1, 2027Sponsor estimate | NCT07734610A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)Merck Sharp & Dohme LLC · Severe Renal Impairment | MRKLead | Phase 1 | Recruiting | Locked | Locked | Locked |
| Feb 5, 2027Sponsor estimate | NCT07743151A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)Merck Sharp & Dohme LLC · Healthy | MRKLead | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Feb 1, 2027Sponsor estimatePhase 1NCT07734610A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)Merck Sharp & Dohme LLC · Severe Renal ImpairmentRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 5, 2027Sponsor estimatePhase 1NCT07743151A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)Merck Sharp & Dohme LLC · HealthyRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 3 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.